Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC265 in Dry Eye Disease
NCT05992922Phase 2Terminated
- Sponsor
- IACTA Pharmaceuticals
- Start
- Oct 2023
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of IC 265 in dry eye disease (DED), sponsored by IACTA Pharmaceuticals. Started Oct 2023; status: terminated.
02
Drugs
IC 265
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05992922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05992922.